编辑文章 - 后台系统

编辑文章

编辑文章

文章标题：

关键字：

所属疾病：

所属类别：

标　　签：

文章主图*

点击“Select image”更换图片

Select image Change Remove

注意! 最佳图片尺寸800*800

内容详情：

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><a href="http://www.india-drugstore.com/p/wenda_detail.php?id=1965&art_cate_value=0&art_navid_value=2"><span style="color:#3498db;"><strong><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">capmatinib</font></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">卡马替尼</font></span></span></span></span></span></span></strong></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">用于治疗转移性非小细胞肺癌（</font><font face="微软雅黑">NSCLC）的成年患者，其肿瘤突变导致间充质-上皮转化（MET）外显子14跳跃</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"> </font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">在非小细胞</font></span></span></span></span></span></span></span><a href="https://www.cancer123.com/types/lung-cancer/"><span class="15" style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">肺癌</font></span></span></span></span></span></span></span></a><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">(NSCLC)中,MET 14外显子跳跃突变(跳读)发生率在3% ~ 4% ,而MET扩增发生率为1%~ 6%。Capmatinib(卡马替尼)是MET受体的选择性抑制剂，在MET激活的各种癌症模型中显示出抗肿瘤活性。卡马替尼是什么药?效果真的有那么好吗?</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">先前接受过</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">capmatinib</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">卡马替尼</font></span></span></span></span></span></span></span><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">治疗且</font> <font face="微软雅黑">MET外显子14跳跃突变患者的ORR为41% ( 28/69 )，中位DOR为9.7个月。先前未接受过治疗的MET外显子14跳跃突变患者ORR为68% ( 19/28 )，中位DOR为12.6个月。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"> </p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑">该研究提示，卡马替尼在晚期NSCLC患者中具有较强的抗肿瘤活性,特别是先前未接受过治疗、GCN较高且MET外显子14跳跃突变的患者。</font></span></span></span></span></span></span></span></span></span></p>

<p style="margin:0pt 0pt 0.0001pt; text-align:justify"><span style="font-size:10.5pt"><span style="font-family:Calibri"><span style="font-size:12.0000pt"><span style="background:#ffffff"><span style="font-family:微软雅黑"><span style="color:#000000"><span style="letter-spacing:0.0000pt"><span style="text-transform:none"><span style="font-style:normal"><font face="微软雅黑"><img alt="" src="../upload/64b643ff73127775854431.jpg" style="width: 900px; height: 746px;" /></font></span></span></span></span></span></span></span></span></span></p>

首页显示：

显示不显示

热门文章：

是否

阅读：